-
Eliem Therapeutics NASDAQ:ELYM Eliem Therapeutics, Inc. is a clinical stage biotechnology company focused on developing therapies for neuronal excitability disorders with the goal of restoring balance in both the peripheral and central nervous systems to help patients live on their own terms. Eliem channels its experience, energy, and passion for improving patients' quality of life by developing life-changing novel therapies for disorders such as chronic pain, depression, epilepsy, focal onset seizures, and anxiety – conditions that make simple daily activities challenging for impacted patients. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.
Location: | Website: eliemtx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
301.4M
Cash
223.1M
Avg Qtr Burn
N/A
Short % of Float
4.08%
Insider Ownership
10.38%
Institutional Own.
77.67%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ETX-810 Details Chronic pain, Pain, Sciatica | Failed Discontinued | |
ETX-810 Details Chronic pain, Sciatica , Pain, Diabetes | Failed Discontinued | |
ETX-155 Details Epilepsy | Failed Discontinued | |
ETX-123 (Kv7.2/3 channel opener) Details Epilepsy, Pain, Seizures | Failed Discontinued | |
ETX-155 Details Major depressive disorder, Perimenopausal Depression | Failed Discontinued |